Recommendation of the President – Staloral 300 (mixture of allergen extracts, allergen extracts of plant origin [plant pollen])
On 6 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 109/2025 on the reimbursement of the medicinal product Staloral 300 (mixture of allergen extracts, allergen extracts of plant origin [plant pollen]) for the indication: Treatment of allergic conditions (type I allergy according to the Gella and Coombs classification), manifested by rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate) in children and adolescents aged 5 to 18 years (aged 5-17 years), in whom the diagnosis has been made on the basis of clinical history and positive skin prick tests and/or specific immunoglobulin E test for grass or birch pollen.